Previous close | 3.0281 |
Open | 3.0920 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 2.7620 - 2.7800 |
52-week range | 1.9947 - 3.7800 |
Volume | |
Avg. volume | 3,726 |
Market cap | 1.939M |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MARSEILLE, France, April 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia and hig
MARSEILLE, France, April 15, 2024--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024
MARSEILLE, France, April 10, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that first preclinical data for its asset IPH45, a novel and differentiated exatecan-Antibody Drug Conjugate (ADC) targeting Nectin-4, were presented in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024.